塔尔克塔马布诱导的幻觉障碍症通过光生物调节疗法成功治疗
Giseli Mitsuy Kayahara1, Raissa Baisso Espinhosa2, Steffani Nascimento da Silva2
1Department of Diagnosis and Surgery, School of Dentistry, São Paulo State University (Unesp), Araçatuba, São Paulo, Brazil.
The Laryngoscope
|July 17, 2025
概括
光生物调制 (PBM) 在多发性骨髓瘤患者中有效治疗了talquetamab诱导的味觉障碍,一种味觉障碍. 这种方法改善了味道敏感性和生活质量,可能防止治疗延迟.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 生物医学工程 生物医学工程
背景情况:
- 多发性骨髓瘤的治疗,特别是复发/耐药病例的治疗,面临着像talquetamab.com这样的新疗法所带来的挑战.
- 塔尔克塔马布是一种针对GPRC5D的双特异性抗体,已被批准用于三级暴露的复发性/耐火性多发性髓瘤.
- 口服的副作用,包括食 (味道变化),是talquetamab治疗中常见的.
研究的目的:
- 报告一个与talquetamab相关的异质症病例,该病例已通过光生物调节 (PBM) 成功治疗.
- 为了评估一个特定的PBM协议在恢复味觉敏感度方面的有效性.
主要方法:
- 一名61岁的患有耐火性多发性骨髓瘤的男性接受了talquetamab治疗,并患有异构症.
- 光生物调制 (PBM) 治疗每48小时使用红色和红外激光装置进行一次.
- 治疗涉及口腔中的78个应用点,具有特定的能量和辐射参数.
主要成果:
- 在7天/3次PBM治疗后,观察到味觉敏感度的显著改善,特别是对于和苦味的味道.
- 在7周的随访期内,味觉敏感性基本保持稳定,盐味感知略有减少.
结论:
- 光生物调制 (PBM) 显示出作为治疗塔尔克塔马布诱导的失灵症的有效治疗的潜力.
- 通过使用PBM来治疗这种口服副作用,可以防止停止治疗,并提高患者的生活质量.
相关概念视频
Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...


